Physician profile
Janice A Ely
NPI 1700800513
$2,040.57
in general payments reported to CMS, 2019-2025
23 companies · $98.27 in 2025
The $98.27 reported for 2025 was less than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $604 · 2023: $276 · 2024: $353 · 2025: $98.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.78 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $290.38 | 2021-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $205.84 | 2021-2023 | |
| Novo Nordisk INC | $195.85 | 2021-2024 | Wegovy |
| Mayne Pharma Commercial LLC | $187.89 | 2021-2024 | |
| Hologic Sales and Service, LLC | $186.23 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $149.09 | 2021-2022 | |
| Daiichi Sankyo INC. | $131.81 | 2021-2023 | Injectafer |
| Pfizer INC. | $113.61 | 2021-2023 | |
| Agile Therapeutics, INC. | $84.18 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $72.63 | 2021-2022 | |
| Scynexis, INC. | $57.25 | 2022 | |
| Myovant Sciences INC. | $47.46 | 2021-2022 | |
| Shield Therapeutics INC | $45.90 | 2023-2024 | Accrufer |
| Avion Pharmaceuticals | $42.67 | 2021-2022 | |
| Exeltis, USA INC. | $37.94 | 2022-2023 | Slynd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $36.71 | 2021-2024 | |
| Vivus LLC | $31.45 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $30.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.22 | 2021 | |
| Evofem Biosciences, INC. | $23.81 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.83 | 2021 | |
| Merck Sharp & Dohme LLC | $15.70 | 2021 | |
| Roche Diagnostics Corporation | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.